|
gptkbp:instanceOf
|
gptkb:antineoplastic_agent
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:Switzerland
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01BC06
|
|
gptkbp:brand
|
gptkb:Xeloda
|
|
gptkbp:CASNumber
|
154361-50-9
|
|
gptkbp:category
|
gptkb:antineoplastic_agent
gptkb:pyrimidine_analog
gptkb:prodrug
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to capecitabine
|
|
gptkbp:developedBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:discoveredBy
|
gptkb:Roche
|
|
gptkbp:eliminationHalfLife
|
0.85 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C15H22FN3O6
|
|
gptkbp:indication
|
gastric cancer
metastatic breast cancer
metastatic colorectal cancer
adjuvant therapy for colon cancer
|
|
gptkbp:KEGGID
|
D01219
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits DNA synthesis
inhibits thymidylate synthase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
D (US)
|
|
gptkbp:prodrugOf
|
gptkb:5-fluorouracil
|
|
gptkbp:proteinBinding
|
54%
|
|
gptkbp:PubChem_CID
|
60953
CHEMBL122
54998
DB01101
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:hand-foot_syndrome
nausea
vomiting
diarrhea
fatigue
neutropenia
|
|
gptkbp:UNII
|
6804DJ8Z9U
|
|
gptkbp:usedFor
|
gptkb:cancer
colorectal cancer
gastric cancer
|
|
gptkbp:bfsParent
|
gptkb:NCT00239681
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Capecitabine
|